ArticleJournal of blood medicine2020

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).

Toshko Lissitchkov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.